NASDAQ:BCAX Bicara Therapeutics (BCAX) Stock Price, News & Analysis $9.07 -0.13 (-1.37%) Closing price 07/3/2025 01:34 PM EasternExtended Trading$9.17 +0.10 (+1.10%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Bicara Therapeutics Stock (NASDAQ:BCAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bicara Therapeutics alerts:Sign Up Key Stats Today's Range$8.85▼$9.4350-Day Range$8.71▼$15.6652-Week Range$7.80▼$28.09Volume248,783 shsAverage Volume601,182 shsMarket Capitalization$494.90 millionP/E RatioN/ADividend YieldN/APrice Target$31.86Consensus RatingBuy Company Overview Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Read More Bicara Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreBCAX MarketRank™: Bicara Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 2410th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBicara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBicara Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Bicara Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bicara Therapeutics are expected to grow in the coming year, from ($2.59) to ($1.74) per share.Price to Book Value per Share RatioBicara Therapeutics has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Bicara Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BCAX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBicara Therapeutics does not currently pay a dividend.Dividend GrowthBicara Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for BCAX. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Bicara Therapeutics this week, compared to 4 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bicara Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders15.50% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Bicara Therapeutics' insider trading history. Receive BCAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAX Stock News HeadlinesBicara Therapeutics Inc News (BCAX) - Investing.comJune 27, 2025 | investing.com# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trialJune 13, 2025 | investing.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 4 at 2:00 AM | Crypto Swap Profits (Ad)BCAX Bicara Therapeutics Inc.June 8, 2025 | seekingalpha.comBicara Therapeutics Expands Boston Headquarters with New LeaseJune 6, 2025 | tipranks.comBicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 3, 2025 | globenewswire.comBicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025June 1, 2025 | globenewswire.comStifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative PatientsMay 26, 2025 | insidermonkey.comSee More Headlines BCAX Stock Analysis - Frequently Asked Questions How have BCAX shares performed this year? Bicara Therapeutics' stock was trading at $17.42 at the beginning of 2025. Since then, BCAX shares have decreased by 47.9% and is now trading at $9.0740. How were Bicara Therapeutics' earnings last quarter? Bicara Therapeutics Inc. (NASDAQ:BCAX) released its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.28. When did Bicara Therapeutics IPO? Bicara Therapeutics (BCAX) raised $315 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 17,500,000 shares at $18.00 per share. How do I buy shares of Bicara Therapeutics? Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/13/2025Today7/04/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCAX Previous SymbolNASDAQ:BCAX CIK2023658 Webwww.bicara.com Phone(617) 468-4219FaxN/AEmployees32Year FoundedN/APrice Target and Rating Average Stock Price Target$31.86 High Stock Price Target$48.00 Low Stock Price Target$8.00 Potential Upside/Downside+251.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio24.62 Quick Ratio24.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.04 per share Price / Book1.00Miscellaneous Outstanding Shares54,540,000Free Float46,083,000Market Cap$494.90 million OptionableN/A BetaN/A The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:BCAX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.The robotics revolution is here. And it's set to impact everything from how we manufacture goods to how we ...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.